Incyte Corporation (INCY) Stock Price Today
Aura AI Summary
Key Stats
- $24.43BMarket Cap
- -Volume
- HealthSector
- $129.9352W High
- $81.6652W Low
- -Typical Hold Time
- $19.93BEnterprise Value
- -Div Yield
- -Trading Activity
Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $81.66 and a high of $129.93, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Most Recent News
Reddit stock set for a major surge after S&P 500 inclusion on August 18, 2026, despite some risks.
Reddit stock has dropped over 22% since early July, making it an attractive buy ahead of its scheduled inclusion in the S&P 500 index on August 18, 2026. This inclusion typically triggers automatic fund buying and significant price spikes, as seen wi...
Pokémon Pokopia sales top 5M on Switch 2, boosting Nintendo shares 7% in Japan
Nintendo announced that Pokémon Pokopia has sold over 5 million units on its Switch 2 console just four months after launch, making it the second-best-selling game on the platform. This strong sales performance helped Nintendo's shares rise 7% in Jap...
Alger Small Cap Growth Fund beats Russell 2000 Growth Index in Q2 2026
The Alger Small Cap Growth Fund's Class A shares outperformed the Russell 2000 Growth Index in the second quarter of 2026. Key contributors to this strong performance included Nebius Group, Astera Labs, and Twist Bioscience, while Insmed, Planet Fitn...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.